Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Inventory (2019 - 2025)

Karyopharm Therapeutics' Change in Inventory history spans 7 years, with the latest figure at $72000.0 for Q4 2025.

  • For Q4 2025, Change in Inventory rose 7.46% year-over-year to $72000.0; the TTM value through Dec 2025 reached -$701000.0, down 141.33%, while the annual FY2025 figure was -$701000.0, 141.33% down from the prior year.
  • Change in Inventory reached $72000.0 in Q4 2025 per KPTI's latest filing, up from -$1.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $1.2 million in Q3 2024 to a low of -$1.0 million in Q3 2025.
  • Average Change in Inventory over 5 years is $69700.0, with a median of $2500.0 recorded in 2022.
  • Peak YoY movement for Change in Inventory: surged 743.8% in 2022, then tumbled 185.79% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $77000.0 in 2021, then crashed by 132.47% to -$25000.0 in 2022, then tumbled by 148.0% to -$62000.0 in 2023, then skyrocketed by 208.06% to $67000.0 in 2024, then increased by 7.46% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Change in Inventory are $72000.0 (Q4 2025), -$1.0 million (Q3 2025), and $223000.0 (Q2 2025).